Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $23.00

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned a consensus rating of “Buy” from the ten brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $23.00.

Several equities analysts have recently weighed in on STOK shares. HC Wainwright reissued a “buy” rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Chardan Capital restated a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, March 18th.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares in the company, valued at $554,550.54. This trade represents a 5.72 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares of the company’s stock, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock worth $143,332 in the last quarter. 11.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new position in Stoke Therapeutics in the 4th quarter valued at about $63,000. Teacher Retirement System of Texas acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. bought a new position in Stoke Therapeutics in the fourth quarter valued at approximately $124,000. Tower Research Capital LLC TRC increased its stake in Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after acquiring an additional 4,918 shares during the last quarter. Finally, Invesco Ltd. acquired a new position in Stoke Therapeutics during the fourth quarter valued at approximately $133,000.

Stoke Therapeutics Stock Up 1.7 %

NASDAQ:STOK opened at $8.29 on Friday. Stoke Therapeutics has a 12-month low of $6.29 and a 12-month high of $17.58. The firm has a market capitalization of $448.31 million, a price-to-earnings ratio of -3.95 and a beta of 0.99. The stock’s 50 day moving average price is $9.46 and its two-hundred day moving average price is $11.35.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The business had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million. Equities research analysts expect that Stoke Therapeutics will post -2.01 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.